Skip to content

VVM Pharma Invest

Active
Private limited companyfounded 2013active for 13 yearsZuiderlaan 35, 8790 Waregem, BelgiumKBO/BCE: BE 0536.716.836

From the official registers: KBO 12 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

VVM Pharma Invest has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €745,240 and a net result of €209,582. Equity is growing by about 19% per year across the filed financial years. Its solvency ranks better than 64% of 573 sector peers (NACE 47, financial year 2026). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow ReportCompare
VVM Pharma InvestActiveChecked score 94/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 04-07-2013 Normal situation
Legal form
Private limited company
Registered office
Zuiderlaan 35, 8790 Waregem
Activity
Retail sale of pharmaceutical products NACE 47730
Establishment unit
2.220.911.208 8790 Waregem, since 16-07-2013
Financial year end
31 March
Peppol
Reachable since 26-11-2025
Company details

Who decides

Board
  • Van Meel StefaanDirector
  • Verhofstede SebastienDirector
Holdings
Shares in 1 company APOTHEEK VERHOFSTEDE
Board & ownership

How it is doing

94 Excellent Checked score 2026
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts to 31-03-2026
Gross margin
€180,523
▲ 3.0%
Turnover
≈ €840,000
estimated
Profit
€209,582
▲ 31.0%
Equity
€745,240
▲ 1.9%
Total assets
€1.7m
▼ 1.9%
2026 accounts 23 days early
Filed on 08-10-2026at the National Bank
Financials
Why 94raises riskSector: Retail trade (NACE 47)lowers riskSize: total assets €1.7mFigures for financial year 2026 (filed 14-10-2026)Founded in 2013Show the evidence

Checked score

Score 2026
94 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 60% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2025
Strong
Solvency 70+2
equity 44.9% of total assets
Liquidity 52-1
short-term debt 12.0% · cash 2.8%
Profitability 85+4
return on assets 12.6%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,270 companies, NACE 47, micro)
Last 24 months 11-2024: 1.7%highest value 12-2024: 1.7%● unchanged vs 11-2024highest value 01-2025: 0.3%▼ -1.4 percentage points vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.4%▲ +0.1 percentage points vs 06-2025 08-2025: 0.5%▲ +0.1 percentage points vs 07-2025 09-2025: 0.6%▲ +0.1 percentage points vs 08-2025 10-2025: 0.3%▼ -0.3 percentage points vs 09-2025 11-2025: 0.3%● unchanged vs 10-2025 12-2025: 0.3%● unchanged vs 11-2025 01-2026: 0.3%● unchanged vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.3%● unchanged vs 02-2026 04-2026: 0.3%● unchanged vs 03-2026 05-2026: 0.1%▼ -0.2 percentage points vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.2%▲ +0.1 percentage points vs 07-2026 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.1%▼ -0.1 percentage points vs 09-2026lowest value
Credit of up to €70,000 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.26, compared with 0.3 in 2025, below 1; short-term debt: 12% and cash: 2.8% of total assets), and 55.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 60% on solvency, 57% on liquidity, 79% on profitability and 45% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Size: total assets €1.7m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Figures for financial year 2026 (filed 14-10-2026)
NBB · annual accounts
lowers risk · Founded in 2013
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 08-10-2026, 23 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
23 days early
2025
37 days early
2024
8 days early
2023
28 days early
2022
34 days early
2021
31 days early
2020
31 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 27 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 3 October (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-03-2027 year end31-10-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage

Key points

  • Positive: Among the best 14% on net resultsector median €23,988 · 573 companies €209,582 View
  • Positive: Filed on time since financial year 2019accounts within the deadline every year 8 years View
  • Positive: 8 profitable years in a rowprofit 2026: €209,582 8 years View

Documents

Annual accounts at the NBB

All 12 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about VVM Pharma Invest

What is the company number of VVM Pharma Invest?
0536.716.836. In Belgium the VAT number is the company number with BE in front: BE 0536.716.836.
Where is VVM Pharma Invest based?
The registered office is at Zuiderlaan 35, 8790 Waregem.Company details
What does VVM Pharma Invest do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of VVM Pharma Invest?
Private limited company (BV).
When was VVM Pharma Invest founded?
On 04-07-2013.
Is VVM Pharma Invest still active?
Yes, VVM Pharma Invest is an active enterprise in the KBO register.
What is the turnover of VVM Pharma Invest?
≈ €840,000 in financial year 2026. Estimated from the gross margin of €180,523: probably between €570,000 and €1.6m, based on 51 comparable companies, NACE 477.Financials
Is VVM Pharma Invest profitable?
In financial year 2026, VVM Pharma Invest made a profit of €209,582.
Where can I find the annual accounts of VVM Pharma Invest?
VVM Pharma Invest filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2026.Annual accounts at the National Bank
When are the next annual accounts of VVM Pharma Invest due?
By 31-10-2027, for financial year 2027.Timeline

Companies related to VVM Pharma Invest

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure